The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon
Official Title: A Study of a Topical Formulation of Nitroglycerin, MQX-503, and Matching Vehicle in the Treatment and Prevention of Raynaud's Phenomenon
Study ID: NCT00577304
Brief Summary: The purpose of this research study is to test the safety, tolerability, and effectiveness of Topical AmphiMatrix with Nitroglycerin (MQX0503) to relieve Raynaud's symptoms and increase blood flow to the fingers.
Detailed Description: The purpose of this clinical study is to determine, in a controlled fashion, the ability of a topical formulation of Nitroglycerin, MQX-503, to improve the patient's health assessment as indicated by patient and physician assessments, decrease the frequency of Raynaud's events, decrease the duration of Raynaud's events, and decrease the symptoms (pain, tingling, numbness) in the fingers of Raynaud's patients. The study will include patients with moderate to severe primary Raynaud's Phenomenon (RP) and with moderate to severe Raynaud's Phenomenon secondary to autoimmune diseases, such as scleroderma.
Minimum Age: 15 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Stanford University, Stanford, California, United States
University of Colorado Health Sciences Center, Denver, Colorado, United States
University of Connecticut, Farmington, Connecticut, United States
Georgetown University, Washington, District of Columbia, United States
University of Chicago, Chicago, Illinois, United States
Johns Hopkins University, Baltimore, Maryland, United States
Boston University, Boston, Massachusetts, United States
Arthritis Education and Treatment Center, PLLC, Grand Rapids, Michigan, United States
University of Minnesota, Minneapolis, Minnesota, United States
University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey, United States
The Center for Rheumatology, Albany, New York, United States
SUNY Stony Brook, Stony Brook, New York, United States
Carolina Arthritis, Wilmington, North Carolina, United States
University of Toledo, Toledo, Ohio, United States
Medical University of South Carolina, Charleston, South Carolina, United States
University of Texas at Houston, Houston, Texas, United States
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Name: Jan Ohrstrom, PhD
Affiliation: MediQuest Therapeutics
Role: STUDY_DIRECTOR